Latest Conference Articles

Isabelle Peene, MD, PhD, recaps efgartigimod data showing maintained CRESS response and low disease activity through 48 weeks in the Sjögren's disease RHO+ OLE.

Sarah Dyball, MBBS, PhD, and Kate Harnden, MBChB, join hosts Rihards Buss, MD, to discuss their research at EULAR 2026.

Laurence Duquenne, MD, PhD, joins Joint Ventures to discuss the TEEMS trial and T-cell stratification.

Denis Poddubnyy, MD, PhD, MSc, discusses how non-nociceptive pain is an important piece of treating the whole AxSpA picture.

Emanuel Della-Torre, MD, PhD, discusses the largest randomized controlled trial in IgG4-RD establishing proof of concept for B-cell inhibition.

Iain McInnes, MD, PhD, discussed comparing bimekizumab and risankizumab for PsA.

Laura Coates, MBChB, PhD, discusses data showing early separation in ACR50 and disease activity measures at week 4, before substantial weight loss.

Laure Gossec, MD, PhD, discusses new research showing early responders maintain greater patient-reported outcome improvements through year 3.

R. Hal Scofield, MD, discusses exploratory biomarker analyses from DAHLIAS investigating serotype, IFN, and IgG subgroups.

The first phase 3 data for filgotinib in axial spondyloarthritis show early, significant, and durable ASAS40 responses with no new safety signals through 52 weeks.

Philip Mease, MD, discusses BE BOLD, which delivers the first head-to-head superiority result for a joint-focused endpoint in psoriatic arthritis.

Xenofon Baraliakos, MD, PhD, discusses significant improvements in BASDAI and ASDAS scores in new late-breaking data from EULAR 2026.

Richard Furie, MD, discusses phase 2 JASMINE data showing sustained SRI-4 and LLDAS responses through 52 weeks.

Novel CAR-T approaches targeting both CD19 and BCMA signal a paradigm shift in systemic sclerosis, alongside a growing focus on early diagnosis.

Richard Furie, MD, discusses a post hoc analysis of BLISS-LN showing a markedly slower rate of kidney function loss with belimumab versus PBO.

Anisha Dua, MD, MPH, discusses the largest US real-world cohort to date in GPA/MPA.

Anisha Dua, MD, MPH, discusses post hoc data from SELECT-GCA that suggest patients with relapsing disease face substantially higher relapse rates.

Phase 2b/3 data show durable ACR50/70, PASI90/100, and minimal disease activity responses with izokibep through one year.

Check out what coverage RheumLive has slated for the upcoming congress in London.

Hosts Jack Arnold, MBBS, PhD, and Rihards Buss, MD, preview the sessions, themes, and abstracts they are most excited about heading into the meeting in London.

The combination showed efficacy in a predominantly female, treatment-experienced, high-BMI population.

Merola discussed how new data from AAD 2026 suggest broader anti-inflammatory properties of GIP/GLP-1 RAs may offer benefits beyond weight loss.

The findings extend the radiographic dataset for risankizumab in PsA to 244 weeks — the longest such follow-up reported from the KEEPsAKE program.

Fleischmann discussed new modalities emerging in the rheumatology field, with the closest frontier in lupus.

Shenoi discussed what the new juvenile arthritis draft guidelines, presented at ACR 2025, emphasized.

Take a look back at 5 RheumLive exclusive conversations ranging from PsA to giant cell arteritis from RWCS 2026 in Maui, Hawaii.

Dua discussed how management of PMR has continued to change over the past couple of years.

Wells and Troum discussed advances in 2025 that are continuing to transform the systemic autoimmune diseases.